Daily Anesthesiology Research Analysis
Three impactful anesthesiology studies stand out today: a high-quality randomized trial shows perioperative dexmedetomidine does not reduce acute kidney injury after partial nephrectomy; a systematic review/meta-analysis finds epidural analgesia offers only a small pain advantage over systemic opioids after VATS; and a large oncologic surgery cohort links asymptomatic postoperative troponin elevations (MINS) to markedly increased early and late mortality, supporting routine surveillance.
Summary
Three impactful anesthesiology studies stand out today: a high-quality randomized trial shows perioperative dexmedetomidine does not reduce acute kidney injury after partial nephrectomy; a systematic review/meta-analysis finds epidural analgesia offers only a small pain advantage over systemic opioids after VATS; and a large oncologic surgery cohort links asymptomatic postoperative troponin elevations (MINS) to markedly increased early and late mortality, supporting routine surveillance.
Research Themes
- Perioperative organ protection and negative RCTs informing practice
- Postoperative risk stratification using cardiac biomarkers (MINS)
- Optimization of thoracic postoperative analgesia strategies
Selected Articles
1. Effect of perioperative dexmedetomidine on acute kidney injury after partial nephrectomy: a single-centre, randomised, double-blind, placebo-controlled trial.
In a randomized, double-blind trial of 288 patients undergoing partial nephrectomy, perioperative dexmedetomidine did not reduce postoperative AKI compared with placebo (22% vs 23%). Kidney function markers up to 6 months and safety outcomes were similar between groups.
Impact: A rigorous RCT provides definitive evidence against using dexmedetomidine to prevent AKI in this surgical population, tempering enthusiasm from preclinical and observational signals.
Clinical Implications: Dexmedetomidine should not be used with the expectation of reducing AKI after partial nephrectomy; its use should be based on other indications (e.g., sedation, sympatholysis). AKI prevention should focus on hemodynamic optimization and nephrotoxin avoidance.
Key Findings
- Postoperative AKI incidence was 22% with dexmedetomidine vs 23% with placebo (RR 0.97; P=0.888).
- No differences in postoperative cystatin C, serum creatinine, or eGFR up to 6 months.
- Safety outcomes were similar between dexmedetomidine and placebo groups.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with modified intention-to-treat analysis
- Prospective registration and assessment of both short- and medium-term renal biomarkers
Limitations
- Single-centre trial may limit generalizability
- Dose/infusion regimen details truncated; potential under- or over-dosing not fully assessable from abstract
Future Directions: Investigate organ-protection strategies targeting modifiable intraoperative factors (hemodynamics, ischemia time) and evaluate alternative pharmacologic renoprotectants in multicentre trials.
BACKGROUND: Acute kidney injury (AKI) is a frequent complication after partial nephrectomy. Dexmedetomidine appears to protect against kidney injury in both in vitro and in vivo. We tested the primary hypothesis that perioperative administration of dexmedetomidine would reduce the incidence of postoperative AKI after partial nephrectomy. METHODS: This randomised, double-blind, placebo-controlled trial was conducted in a tertiary care hospital in Beijing, China with 290 participants randomly assigned to receive dexmedetomidine or saline at a loading dose of 0.6 μg kg RESULTS: Two surgeries were cancelled after randomisation, leaving 288 participants (mean age [range]: 55 [20-79] yr; 32% female) for the modified intention-to-treat analysis. AKI occurred in 32/144 (22%) participants randomly assigned to dexmedetomidine, compared with 33/144 (23%) participants randomly assigned to saline (risk ratio 0.97; 95% confidence interval 0.63-1.49; P=0.888). Secondary outcomes, including postoperative serum cystatin C and serum creatinine levels and estimated glomerular filtration rate in postoperative 6 months, were not different between groups. The incidence of safety outcomes was similar in each group. CONCLUSIONS: Perioperative dexmedetomidine administration did not reduce postoperative AKI after partial nephrectomy. CLINICAL TRIAL REGISTRATION: ChiCTR2200059536.
2. Epidural Analgesia Versus Systemic Opioids for Postoperative Pain Management After VATS: A Systematic Review and Meta-Analysis.
Across 4 RCTs and 4 observational studies (n=946), epidural analgesia after VATS reduced pain scores modestly compared with systemic opioids (about 0.8 points at rest and 1.1 during activity over POD1–3), with substantial heterogeneity. Within multimodal regimens, the clinical advantage may be small.
Impact: Synthesizes the best available evidence to inform whether regional analgesia can be safely omitted in select VATS patients without compromising pain control.
Clinical Implications: In centers practicing multimodal analgesia, systemic opioids may be a reasonable alternative to epidural for some VATS patients, balancing small pain benefits against procedural risks and contraindications. Individualize based on risk of neuraxial complications and patient preference.
Key Findings
- Primary RCT meta-analysis: epidural analgesia reduced pain by 0.8 NRS/VAS points at rest (95% CI 0.2–1.3).
- During activity, epidural reduced pain by 1.1 points (95% CI 0.7–1.5) over POD1–3.
- High heterogeneity and moderate certainty; overall benefit may be small within multimodal analgesia strategies.
Methodological Strengths
- Prospectively registered (PROSPERO CRD42024598757) systematic review and meta-analysis
- Included both rest and activity pain across multiple postoperative days with RCT-focused primary analysis
Limitations
- Substantial heterogeneity; analgesic regimens and multimodal co-interventions varied
- Mix of RCTs and observational studies; potential confounding in nonrandomized data
Future Directions: Adequately powered multicentre RCTs comparing epidural, paravertebral/ESP blocks, and systemic strategies within standardized multimodal pathways, with patient-centred outcomes and safety.
BACKGROUND: Firm consensus on the best perioperative pain management after Video-Assisted Thoracic Surgery (VATS) is lacking. Recommendations often assess different loco-regional techniques as part of a multimodal approach, but few discuss omitting regional analgesia altogether, eliminating any risk of procedural complications. A reasonable prerequisite for this approach would be that the alternative provides comparable pain relief. To compare the efficacy of systemic opioids and epidural analgesia for postoperative pain management, we conducted a systematic review and meta-analysis of current studies. METHODS: We did a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies on VATS with the primary objective of examining postoperative pain at rest and during activity at POD1, POD2, and POD3. The secondary objectives were to evaluate the efficacy of the treatments, examining the need for postoperative "rescue" opioid, the hospital length of stay, and side effects. We did literature searches of Medline, Embase, and the Cochrane Library from inception to 07 April 2025. Additionally, we searched ClinicalTrials.gov, the EU Clinical Trials Register, the WHO International Clinical Trials Registry Platform, Scopus, and Google Scholar. We included adult patients undergoing VATS receiving either epidural analgesia or systemic opioids for postoperative pain management. RESULTS: We included four randomized controlled trials (RCTs) and four observational studies encompassing 946 patients. The primary meta-analysis of the RCTs found that epidural analgesia reduced pain compared with systemic opioids by a pooled mean difference of 0.8 NRS/VAS points (95% CI 0.2-1.3) at rest and 1.1 points (0.7-1.5) during activity over POD 1 to 3. Heterogeneity was substantial (I CONCLUSION: Epidural analgesia offers a small but possibly subclinical reduction in acute postoperative pain after VATS compared with systemic opioids, particularly when combined with baseline multimodal analgesia. High heterogeneity and moderate certainty underscore the need for adequately powered trials. PROSPERO REGISTRATION: CRD42024598757.
3. Myocardial injury and short- and long-term outcomes after oncological surgery: A large-scale retrospective cohort study.
In 6,277 adults undergoing intermediate-to-high-risk oncologic surgery, MINS (hsTnI >26 ng/L) occurred in 19.1% and was largely asymptomatic. MINS independently predicted 30-day mortality (aHR ~7) and sustained excess mortality risk through 1 year, supporting routine postoperative troponin surveillance and targeted interventions.
Impact: Provides robust, oncology-specific evidence that asymptomatic troponin elevations are common and clinically meaningful, quantifying their contribution to early and late mortality.
Clinical Implications: Implement routine postoperative hs-troponin surveillance in intermediate-to-high-risk oncologic surgeries to detect MINS, guide monitoring/intensification of therapy, and inform shared decision-making and follow-up.
Key Findings
- MINS occurred in 19.1% of patients; 98.7% were asymptomatic.
- MINS independently predicted 30-day mortality (aHR 7.10) and contributed 53.8% of population-attributable risk.
- Elevated hsTnI associated with dose-dependent increases in 30-day mortality and MACE; excess mortality risk persisted through 1 year.
Methodological Strengths
- Large sample with systematic postoperative hsTnI measurement and advanced modeling (restricted cubic splines, landmark and flexible parametric survival analyses)
- Robust sensitivity analyses excluding nonischemic elevations; risk reclassification metrics reported
Limitations
- Retrospective single-institution design with potential selection bias (only patients with postoperative hsTnI measured)
- Causality cannot be inferred; specific management responses to MINS not evaluated
Future Directions: Prospective trials testing MINS-guided care pathways (e.g., intensified hemodynamic optimization, antithrombotic or cardioprotective strategies) and external validation across cancer types and institutions.
BACKGROUND: Myocardial injury after noncardiac surgery (MINS) significantly contributes to perioperative mortality, yet its incidence and prognostic value in patients undergoing oncological surgery remain inadequately characterized. METHODS: In this retrospective cohort study, we analyzed 6277 adults (mean age 58.9 years; 60.0 % male) undergoing intermediate-to-high-risk oncological surgeries between September 2013 and September 2022 with postoperative high-sensitivity troponin I (hsTnI) measurements. Dose-response relationships between peak hsTnI and the outcomes of 30-day mortality and 30-day major adverse cardiovascular events (MACE) were modeled using multivariable Cox regression with restricted cubic splines. MINS was defined as an ischemic hsTnI elevation >26 ng/L. Long-term (365-day) mortality was analyzed using both 30-day landmark analysis and flexible parametric survival model (FPSM) to account for potential time-varying effects. RESULTS: Each standard deviation increase in log-transformed hsTnI was associated with a twofold higher risk of 30-day mortality (adjusted hazard ratio [aHR] 2.33, 95 % CI: 1.94-2.80; P < 0.001) and a nearly fourfold higher risk of 30-day MACE (aHR 3.91, 95 % CI: 3.47-4.42; P < 0.001). After excluding 22 patients with nonischemic troponin elevations, MINS occurred in 19.1 % of patients, with 98.7 % being asymptomatic. MINS independently predicted 30-day mortality (aHR 7.10, 95 % CI: 4.21-11.97; P < 0.001) and accounted for 53.8 % of the population-attributable risk. Adding MINS modestly improved the C-index for 30-day mortality prediction (0.831 vs. 0.797; ΔC-index, 0.034; P = 0.090) but significantly improved risk reclassification (net reclassification improvement, 31.51 %) and discrimination (integrated discrimination improvement, 0.037). Landmark analysis showed an 8.1-fold increased risk within 30 days and a sustained 1.8-fold risk from day 31 to 365. FPSM confirmed a sustained excess mortality hazard throughout the year. CONCLUSIONS: MINS is common, largely asymptomatic, and strongly associated with both early and late mortality after oncological surgery. Routine troponin monitoring may help identify high-risk patients for intervention.